Skip to content

Exagen Inc. XGN Current ratio

Current ratio at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
1.7×-0.1×
Quest Diagnostics logo
Quest DiagnosticsDGX
1.2×-0.3×
Vor Biopharma logo
Vor BiopharmaVOR
31.1×+27.3×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
CareDx logo
CareDxCDNA
3.4×-0.7×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
3.2×-2.8×

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×

Where this comes from

Calculated from Exagen Inc.’s reported figures.

Based on the most recent quarter.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s current ratio?
Exagen Inc. (XGN) reported current ratio of 3.5× in Q1 2026.
How has Exagen Inc.'s current ratio changed year-over-year?
Exagen Inc.'s current ratio increased by 49.4% year-over-year, from 2.3× to 3.5×.
What is the long-term trend for Exagen Inc.'s current ratio?
Over 5 years (2020 to 2025), Exagen Inc.'s current ratio has grown at a -15.6% compound annual growth rate (CAGR), from 8× to 3.5×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.